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T  cells recognize short linear peptides bound to major histocompatibility complex (MHC)- 
encoded  molecules.  Subtle  molecular  changes  in  peptide  antigens  produce  altered  peptide 
ligands  (APLs), which  induce  different T  cell responses from those induced  by the antigenic 
ligand. A molecular basis for how these slight molecular variations lead to such different conse- 
quences for the T  cell has not been described. To address this issue,  we have made amino acid 
substitutions at the primary T  cell receptor (TCR) contact residue of the murine hemoglobin 
determinant,  Hb(64-76)/I-E  k and  produced  12  peptides  that  interact  with  the  TCR  of the 
T  cell clone 3.L2.  The 3.L2  T  cell responds to these peptides, which vary 1 million-fold in 
their activity, and enables them to be ranked according to their relative ability to signal through 
the 3.L2 TCR.  Such a ranking reveals that the ability of the 3.L2 T  cell to respond to these 
peptides depends on how well the structure of the side chain at the primary TCR contact site 
mimics that of the Asn residue present in the antigenic ligand. The reactivity of the 3.L2 T  cell 
also depends on an MHC contact residue that is next to the primary TCR contact residue, sug- 
gesting that conformation of the Asn side chain is also important. By using nonnatural amino 
acids at a TCR  contact residue,  we have demonstrated that APLs can be rationally designed 
based on structure.  These data are consistent with a model in which the affinity of a peptide- 
MHC complex for the TCR determines how the T  cell will respond. 
C 
ell-mediated immunity is dependent on the activation 
of antigen-specific  0e/J3 T  cells.  This  activation  de- 
pends  ultimately on  the  ability of a  TCR  to  recognize  a 
complex composed of an 8-20-amino acid peptide bound 
to a protein encoded by the MHC (1, 2). A molecular un- 
derstanding  of this interaction is required  in  order to  un- 
derstand antigen-specific immunity. Although this interac- 
tion  is  highly  specific,  there  is  a  surprising  amount  of 
flexibility in this recognition event. A  TCR can recognize 
ligands that are slightly altered, and recognition of these al- 
tered ligands can lead to dramatic functional consequences 
for the  T  cell  (3).  A  knowledge of the structural basis  for 
the  interaction  between  the  TCR  and  altered  ligands  is 
therefore important if we are to understand T  cell recogni- 
tion and antigen-specific immunity. 
Flexibility  in  TCP,.  recognition  of ligand  was  initially 
demonstrated using a T  cell clone that produced IL-4 and 
proliferated  in  response  to  its  wild-type  ligand  but  pro- 
duced IL-4 in the absence of proliferation in response to a 
single-amino acid variant of the antigenic peptide (4). This 
finding showed that a subtle change in the ligand did not 
completely eliminate TCR. recognition, but the TCR could 
still  recognize  the  altered  peptide  ligand  (APL) I.  Subse- 
quently, it has been shown that TCR recognition of APLs 
can lead to a variety of responses from the T  cell,  many of 
which are fundamentally different from that induced by the 
wild-type  ligand  (5).  These  altered  responses  include  cy- 
tokine production in the absence of proliferation, differen- 
tial cytokine production, anergy, and antagonism of the re- 
sponse to the wild-type antigen (4, 6-8). 
Evidence suggests that flexibility in recognition ofligand 
is an essential feature of the life and function of T  cells.  In 
particular, thymic development of T  cells may depend en- 
tirely on the ability of the TCR to interact with a subopti- 
mal ligand (9).  Fetal thymic organ culture experiments us- 
ing  thymi  from mice  expressing  a  transgenic  TCR  have 
shown that positive and negative selection ofT cells can be 
mediated  by peptides  closely related  to  the  cognate  anti- 
genic peptide  (10-13).  Because  of the  flexibility in  TCR 
ligand recognition, a few selfpeptides may be able to select 
~  Abbreviations used in this paper: Abu, o~-aminobutyric  acid; APL, altered 
peptide ligand; MCC, moth cytochrome  C; Nva, norvaline; Pra, propyl- 
argylglycine. 
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a vast array of foreign antigens.  Additionally,  numerous in 
vitro  studies  of cloned  T  cell  lines  have  clearly  demon- 
strated that peripheral T  cells  have retained the capacity to 
recognize  suboptimal  ligands.  The  two  main  effects  that 
APLs have  on peripheral  T  cells  are  to  act  as  antagonists 
and inhibit the T  cell response (8,  14-16), or to act by forc- 
ing  production  of a  certain  pattern  of cytokines  (6,  17). 
These effects can potentially lead to subversion of the im- 
mune  response by a virus,  and  also raise  the possibility of 
treatment of autoimmune diseases  with APLs. 
Although it is clear that APLs play a major role in the life 
of T  cells,  a  structural  basis  for  how  APLs  interact  with 
TCP,, and how this relates to a change in function, has not 
been  established.  Our  aim  is  to  understand  the  structural 
basis  for the  interaction  of the  TCtL with  APLs.  Such an 
understanding  would help  to  answer  two  main  questions. 
First,  we would like  to know the molecular basis for how 
recognition of an APL is different from recognition of the 
wild-type ligand. This understanding would lead to knowl- 
edge of how APL recognition leads to a different T  cell re- 
sponse and better understanding of the general mechanisms 
underlying T  cell recognition  of MHC  and T  cell activa- 
tion.  Second,  we  would  like  to  identify  principles  that 
would allow a rational design of APLs. The potential use- 
fulness of APLs makes it important to be able to easily pro- 
duce them once the sequence of a peptide antigen has been 
determined.  Guiding  principles  for  APL  design  would 
therefore be of great benefit. 
The  differences  between  peptides  that  act as  APLs and 
their  wild-type  counterparts  have  so  far  been  difficult  to 
categorize.  Crystallographic  studies  of antigenic  peptide- 
MHC  complexes have revealed that the peptide fits  into a 
binding site that leaves much of the peptide inaccessible for 
recognition  (18-21).  Some  amino  acid  side  chains  of the 
peptide do, however, protrude from the surface of the MHC 
molecule  and  are  available  for interaction  with  the  TCP,. 
In  general,  peptides  have  three  or  four  residues  that  are 
available  to  contact  the  TCtL  and,  together  with  amino 
acid side chains from the MHC molecule, make up the sur- 
Face thought to interact with the TCP, directly. Therefore, 
the surface made up of both peptide and MHC is the ligand 
recognized by a  TCR  and  will  change  if the  peptide  se- 
quence is changed. 
Most APLs have been generated empirically, by making 
changes in the few TCR  contact residues of the peptide. A 
study of the DILl-restricted 307-319 hemagglutinin peptide 
epitope  suggested  that  only  conservative  substitutions  at 
TCP, contact residues would yield APLs (22).  However, a 
study of an H-2Kb-restricted  ovalbumin peptide  was unable 
to  draw  any  correlation  between  the  type  of substitution 
made and how the TCI% responded (23). Our own experi- 
ence  with  the  I-Ek-restricted  hemoglobin  64-76  epitope 
has been that substitutions at TCR  contact residues are the 
most likely places to find APLs, but that the limited num- 
ber of side chains that we have been able to find at any one 
position that interact with a single TCR  have made it im- 
possible to draw any conclusions about what makes an el- 
fective substitution.  The lack of a paradigm for the rational 
design  and  function  of APLs makes  a  systematic  study  of 
the recognition of a single TCtk contact residue necessary. 
We have carefully examined recognition by the  3.L2 T 
cell of the Hb(64-76) peptide bound to I-E  k (24). By mak- 
ing amino  acid  changes  in  the  P5  residue  of this  peptide 
that  is  known  to  point  toward  and  interact  directly  with 
the TCR, we have identified peptides that can act as weak 
agonists or as APLs for a particular TCR  over an extensive 
activity range. These amino acid substitutions have allowed 
us to identify properties  of this  TCtL contact residue  that 
allow it to induce a T  cell response. Based on this knowl- 
edge,  we  have  produced  APLs  containing  nonnatural 
amino acid substitutions  to which the T  cell responds in a 
predictable  manner.  Such peptides  are potentially valuable 
tools in  the  manipulation  of immune  responses  and  show 
that recognition of APLs has a structural basis. 
Materials  and Methods 
Cells.  The 3.L2 Thl clone and the 3.L2.12 T cell hybridoma 
were grown in R.PMI 1640 supplemented with  10% FCS (Hy- 
clone Laboratories Inc., Logan,  UT), 2  ￿  10 -s M  13-ME, 2 mM 
Glutamax  (GIBCO  BRL,  Gaithersburg,  MD),  50  I~g/ml  gen- 
tamicin,  and 10 mM Hepes. The 3.L2 Thl  clone was derived as 
described previously  (24) and is specific for the Hb(64-76) peptide 
as presented by the I-E  k MHC class II molecule. The 3.L2.12 hy- 
bridoma was  derived by polyethylene glycol fusion  of the 3.L2 
Thl  clone to the BW5147 cx-~3- thymoma (25). Both the 3.L2 
clone and the 3.L2.12 hybridoma are CD4 +, and the role of CD4 
in the response of these cells is currently under investigation.  The 
3.L2 clone and the 3.L2.12 hybridoma use the same TCP,. based 
on the fact that we can account for all of the TCIL on the surface 
of these  cells by staining  with an anti-TCtL clonotype antibody. 
Furthermore,  we have found that the TCP, recognized by the 
anticlonotype antibody is responsible  for the observed activity by 
transfection  of the proper TCR. chains  into the TCP,-negative 
58ot-[3-  hybridoma (data not shown).  The  CH27  B  cell  lym- 
phoma expresses the I-Ek/I-A  k MHC class II molecules  and was 
grown in RPMI media supplemented as described  (26). 
Peptides.  Peptides  were  synthesized  using  standard  Fmoc 
chemistry on a multiple  peptide  synthesizer  (Symphony/Multi- 
plex;  Protein  Technologies Inc.,  Tuscon, AZ).  Fmoc-Nva was 
purchased from Calbiochem-Novabiochem (La Jolla,  CA),  and 
the  remaining  Fmoc-protected amino acids as well  as Lys-cou- 
pled resin were purchased from Advanced Chemtech (Louisville, 
KY).  Peptides  were purified  on a C1~ reverse-phase  HPLC col- 
umn. The C72 peptide was resuspended  at 2 mM in an aqueous 
solution of 100  mM  [3-ME before HPLC purification,  and the 
purified,  reduced C72 peptide was stored under nitrogen. Amino 
acid content and accurate  concentrations of all peptides  were de- 
termined  by  analysis on  an  amino  acid  analyzer  (model  6300; 
Beckman Instruments, Inc., Fullerton,  CA) and comparison with 
a standard  of known concentration. The purity and accuracy of 
each of the peptides  were confirmed by mass spectrometry at the 
Washington  University  Mass Spectrometry  Resource.  Altered 
peptides  of Hb(64-76) are referred to using the one-letter amino 
acid code for the substituted  amino acid, followed by its position. 
For example,  A72 refers  to an Hb(64-76)  peptide  that has Ala 
substituted  for Asn at position 72. The amino acid residues them- 
selves are referred to by their  three-letter  codes. Therefore,  Asn72 
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amino acids, the three-letter codes are used to refer both to the 
peptides and to the amino acid residues. The names and sequences 
of the peptides  used  in this  study are  as follows:  Hb(64-76)  = 
GKKVITAFNEGLK;  A72  =  GKKVITAFAEGLK;  C72  = 
GKKVITAFCEGLK;  D72  =  GKKVITAFDEGLK;  E72  = 
GKKVITAFEEGLK;  F72  =  GKKVITAFFEGLK;  G72  = 
GKKVITAFGEGLK;  H72  =  GKKVITAFHEGLK;  172  = 
GKKVITAFIEGLK;  K72  =  GKKVITAFKEGLK;  L72  = 
GKKVITAFLEGLK;  M72  =  GKKVITAFMEGLK;  P72  = 
GKKVITAFPEGLK;  Q72  =  GKKVITAFQEGLK;  1<72  = 
GKKVITAFREGLK;  $72  =  GKKVITAFSEGLK;  T72  = 
GKKVITAFTEGLK;  V72  =  GKKVITAFVEGLK;  W72  = 
GKKVITAFWEGLK; Y72  =  GKKVITAFYEGLK; Abu72  = 
GKKVITAF(Abu)EGLK;  Pra72  =  GKKVITAF(Pra)EGLK; 
Nva72  =  GKKVITAF(Nva)EGLK; D73  =  GKKVITAFN- 
DGLK; C72D73 =  GKKVITAFCDGLK; T72D73 =  GKKVIT- 
AFTDGLK; and V72D73 =  GKKVITAFVDGLK. 
Peptide Binding to I-EL  The relative ability of all of these pep- 
tides to bind I-E  k was determined by assaying the ability of the 
peptides  to compete with a peptide composed of amino acids 92- 
103 of moth cytochrome C  (MCC) for binding and thereby in- 
hibit the response  of the T cell hybridoma 2B4. To measure  this 
competition for binding to available cell surface I-E  k molecules, 
105 2B4 cells were incubated with 2 X 104 CH27 in the presence 
of 0,2  ~M MCC peptide plus a titration of the Hb(64-76) pep- 
tide or one of its analogs. Supernatants were collected  20 h later 
and assayed for IL-2 production using the CTLL-2 cell line. The 
Hb(64-76) peptides all gave a 50% inhibition  of the 2B4 response 
at a concentration between 10 and 100 btM. 
T Cell Hybridoma Assay.  Stimulation of T cell hybridomas was 
determined by measuring IL-2 production using the IL-2-depen- 
dent cell line CTLL-2 (24). 
Antagonist Assay.  A previously described  assay for TCIK an- 
tagonism of a T cell hybridoma was used (8, 27). CH27 cells were 
prepulsed with the Hb(64-76) peptide by incubation of 3 X  10  ~ 
CH27 cells in 2 ml IKPMI media with 0.1  I.tM Hb(64-76) pep- 
tide for 2 h at 37~  After washing three times, 2 X 104 prepulsed 
CH27 cells were added to wells of a 96-well plate containing 105 
T  cell hybridoma cells in 200 ~1 of IKPMI media and a titration 
of potential antagonist peptides. After 20 h of incubation at 37~ 
supernatant was assayed for IL-2 content using CTLL-2. 
Apoptosis Assay.  Apoptosis  of the CH27  cells was assayed as 
previously described  (26). Briefly, 3 ￿  10  ~' CH27 cells were radi- 
olabeled by incubation for 5 h in 1 ml of R.PMI 1640 media con- 
taining 4 mCi [3H]thymidine. After washing three times, 3 ￿  104 
radiolabeled  CH27 cells were cultured with  105 3.L2 T  cells in 
the presence  of the indicated peptides.  24 h later, cells were har- 
vested, and apoptosis was quantitated by liquid scintillation count- 
ing. Apoptosis  results in a decrease  in the number of recovered 
counts due to fragmentation of the labeled DNA. The EC40 of 
these peptides  was calculated  as the concentration of peptide re- 
quired to reduce the amount of recovered counts by 40%. This 
percentage was selected in order to include all of the peptides that 
were positive in the assay. 
Results 
The Hb(64-76)Epitope.  Previous  studies  have  charac- 
terized the  binding of the  Hb(64-76)  peptide  to  the  I-E  k 
class  II  MHC  molecule and recognition of that peptide- 
MHC complex by TCRs (Fig. 1)  (4,  24, 25). Amino acids 
Ile68 and Lys76 of Hb(64-76) are the main MHC  anchor 
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residues, although Phe71  and Glu73 also interact with the 
MHC. Comprehensive studies of a panel of 11 Hb(64-76)- 
specific  T  cells  have  shown  that  residues  Thr69,  Ala70, 
Ash72,  and Leu75  are  important for  interaction with the 
TC1K (4, 24, 25). Importantly, postition 72 has been desig- 
nated the primary T  cell contact residue because almost all 
T  cells that respond to  the  Hb(64-76)  epitope focus their 
recognition intensely on  this  position.  In fact,  all T  cells 
isolated so far that respond to Hb(64-76) will not respond 
to  a  variant of Hb(64-76)  that has the Ash at position 72 
substituted with a Gln (Q72), a change that adds one meth- 
ylene group. Recently, the crystal structure for the Hb(64- 
76)  peptide  complexed  to  I-E  k  has  been  solved,  and  it 
shows  that Asn72 is positioned in the  center of the  pep- 
tide-MHC complex and points directly up from the  sur- 
face of the MHC molecule in an ideal position to interact 
with the TC1K (21). The structure also reveals that Glu73 is 
an MHC-binding residue, and its side chain is inaccessible 
to the TCR. This finding was unanticipated becase a pep- 
tide with a Glu-to-Asp mutation at position 73 (D73) binds 
to  the  MHC  equally as well as the wild-type peptide but 
interacts with the TC1K in a different manner (4,  24, 25). 
Although most T  cells that are reactive with the Hb(64- 
76)  peptide  only recognize Ash at position 72,  we  found 
that the CD4 + T  cell clone 3.L2 will tolerate some changes 
at the 72 position. Because we knew that side chains at this 
position would interact directly with the  TCR,  our goal 
was to identify APLs for the 3.L2 T  cell that were created 
by single-amino acid changes at position 72 of Hb(64-76). 
We reasoned that the identification of the side chain struc- 
tures that  are  able to  interact with the  3.L2  TC1K would 
show how subtle variations in the structure of a ligand can 
influence T  cell response. We have therefore characterized 
the ability of the 3.L2 T  cell to respond to Hb(64-76) pep- 
tides  that bear mutations at position 72,  encompassing all 
19 other naturally occurring amino acids. 
Identification of Peptides That Induce a Response through the 
3.L2 TCR.  For the initial characterization of these pep- 
tides,  we  have used the  3.L2.12  hybridoma, a  CD4  +  cell 
line that was derived from the 3.L2 T  cell clone. This hy- 
bridoma uses  the  same  TCR  as  the  3.L2  clone based on 
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Figure 1.  A representation  of the Hb(64-76) epitope. The sequence  of 
this peptide is shown using the standard one letter amino acid code. Based 
on  a combination of mutational analyses and the  crystal structure of 
Hb(64-76) complexed to I-E  k, residues of the peptide can be designated 
to interact with the MHC molecule or primarily  with the TC1K. Arrows 
pointing down indicate the residues that interact with the MHC mole- 
cule, and the upward pointing arrows indicate the TCR contact residues. 
The primary MHC anchor residues are I1e68 and Lys76, and the Asn at 
position 72 interacts  exclusively  with the TCR. 40000 
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Figure 2.  Identification  ofagonist peptides for the 3.[,2 TCR. Hb(64- 
76) peptides bearing all 20 natural amino acids at position 72 were tested 
for their ability  to stimulate  IL-2 production from the 3.L2.12 hybridoma. 
The nonnatural amino acids Abu, Nva, and Pra were also substituted at 
position 72 and tested for their ability  to stimulate  3.L2.12. In addition, a 
peptide with a Glu-to-Asp mutation at position 73 was also tested. The 
following peptides are not displayed  on the graph but behaved identically 
to the R72 peptide and gave no stimulation  at concentrations  as high as 
100 ~M: A72, D72, E72, F72, G72, H72, I72, K72, L72, M72, P72, 
Q72, $72, W72, Y72, Pra72, and Nva72. IL-2 production was deter- 
mined by proliferation  of CTLL-2 cells. The values  represent the mean of 
triplicate wells, and the SDs were <15% of the mean. Positive peptides 
were tested at least four times, and negative peptides were tested at least 
two times. 
staining with an anticlonotypic antibody and gene transfer 
studies. Therefore, the 3.L2.12 T  ceil hybridoma gives us a 
convenient method to analyze the panel ofpeptides for the 
ability to act as agonists or antagonists for the 3.L2  TCR. 
All of the substituted peptides used in this study bind the 
I-E  k MHC  molecule with a  similar affinity (see  Materials 
and Methods),  and  the  crystal  structure  of the  wild-type 
Hb(64-76)  peptide shows  that  the  Asn at position 72  has 
minimal interactions with the MHC molecule (28). There- 
fore  we presume that the peptides used in this study that 
are substituted at position 72 bind to the MHC molecule in 
the same manner and that all of the position 72 side chains 
point toward the TCR and are available for interaction. 
We first tested these peptides for their ability to stimulate 
the 3.L2.12 hybridoma to produce IL-2 and thereby act as 
agonists. This resulted in the identification of three peptides 
substituted at the 72 position that are weak agonists for the 
3.L2 TCR  (Fig. 2). The peptides C72, T72, and V72 reca- 
pitulate  the  activity  of the  Hb(64-76)  peptide  at  higher 
concentrations. Hb(64-76) stimulates IL-2 production at a 
dose  as low as 0.01  IxM, whereas the peptides C72,  T72, 
and  V72  require  a  10-100-fold  higher  concentration of 
peptide to achieve the same effect.  All other naturally oc- 
curring amino acids at  position 72  failed to  stimulate any 
IL-2 production from 3.L2.12 at doses up to 100 IxM (Fig. 
2 and data not shown). 
We  next  wanted  to  determine  if among  the  peptides 
substituted at position 72 that were negative in the agonist 
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Figure 3.  Identification  of antagonist  peptides for the 3.L2 TCR. All of 
the Hb(64-76) peptides substituted  at position 72 that failed to act as ago- 
nists for the 3.L2 TGR were tested for the ability to act as antagonists. 
APCs were prepulsed with 0.1 I~M of the wild-type Hb(64-76) peptide 
and stimulated  the 3.L2.12 hybridoma  to the level indicated  by the dashed 
line. The graph shows those peptides that gave a dose-dependent  inhibi- 
tion of this response, as well as one peptide (E72) that did not act as an an- 
tagonist. The peptides W72, P72, Q72, E72, R72, K72, F72, and H72 all 
failed to antagonize and were tested two times at concentrations up to 
316 IxM. The peptides M72, D72, and Y72 gave a slight inhibition at 
concentrations >100  IxM. The values represent the mean of triplicate 
wells, and the SDs were <15% of the mean. 
assay,  there  were  any peptides  that  could act  as APLs  for 
the 3.L2 TCR. We tested these remaining peptides by as- 
saying for the ability to antagonize the 3.L2.12 hybridoma 
response to  Hb(64-76)  (Fig.  3).  I72,  $72,  A72,  L72,  and 
G72  all showed  a  dose  dependent antagonism of the  re- 
sponse to  wild-type Hb(64-76).  The peptides W72,  P72, 
Q72, E72, R72, K72, F72, and H72 all failed to yield any 
detectable antagonism even at concentrations as high as 316 
IxM. The peptides M72, D72, and Y72 did inhibit the re- 
sponse of 3.L2.12 slightly, but only at concentrations > 100 
IxM.  It is possible that such slight antagonism at very high 
concentrations may be significant, but in this study we did 
not consider these very weak antagonist peptides further. 
The  two  assays  described  above  enabled us  to  identify 
three agonists and five antagonists for the 3.L2 TCR. Based 
on our knowledge of the structure of the Asn at position 72 
and the structures of the other side chains to which 3.L2.12 
responded,  we  next  attempted  to  rationally design  APLs 
using peptides  substituted at  position 72  with  nonnatural 
amino acids. Because G72 is a weak antagonist and A72 is a 
more  active  antagonist, we  reasoned that  side  chains that 
extended  a  straight  aliphatic  side  chain  further  than  Ala 
would possibly more closely mimic the size of Ash and in- 
duce  a  more  potent  response  through  the  3.L2  TCR. 
Therefore,  we  tested  peptides  substituted  at  position  72 
with c~-aminobutyric acid (Abu) and norvaline (Nva). Abu 
has a straight aliphatic side chain of two carbons, and Nva 
has  a straight three-carbon side chain (Fig.  4).  Abu72 is a 
weak agonist for the 3.L2  TCR  and is in fact the peptide 
that  comes  closest  to  recapitulating  the  activity  of  the 
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Figure 4.  Relative activities of 
peptides  that  interact  with  the 
3.L2 TCR,  12 peptides that dif- 
fer  only in  the  structure  of the 
amino acid side chain at position 
72  of Hb(64-76) were  ranked 
according to their ability to stim- 
ulate through the 3,L2 TCR_  A 
schematic diagram of the struc- 
tures of the side chains of these 
amino  acids  at  position  72  is 
shown.  The  wild-type  Hb(64- 
76)  peptide has an Ash at  posi- 
tion  72  and  has been arbitrarily 
assigned an activity of 100.  The 
EC40  of  the  peptides  Abu72 
through  A72  was  determined 
from the apoptosis assay (Fig.  5), 
and these numbers were used to 
assign  an  activity  of these  pep- 
tides  relative  to  the  wild-type 
peptide.  Because $72,  L72,  and 
G72 had no activity in the apop- 
tosis  assay, a  relative activity for 
these peptides was  estimated by 
comparing the  concentration  of 
these  peptides  required  for  an- 
tagonist  activity  with  that  re- 
quired  for  A72.  Parentheses 
placed around the relative activi- 
ties  for  these  peptides  indicate 
that  these  activities  are  derived 
by extrapolation. 
Hb(64-76)  peptide (Fig. 2).  Nva72 is an antagonist for the 
3.L2  TCR  and is active at ~10-fold lower concentrations 
than  the A72 peptide (Fig. 3).  We next wanted to test an 
amino  acid at position 72  that  not  only resembled Asn in 
size but also could possibly mimic some of the chemical na- 
ture  of the amide group. We therefore synthesized a pep- 
tide  that  used  propargylglycine  (Pra)  at  position  72,  an 
amino acid that is thought to be able to mimic an Asn side 
chain. Like Nva, Pra has a straight three-carbon side chain, 
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but in Pra the last two carbons are joined by a triple bond 
(Fig. 4) (29, 30). The Pra72 peptide was a very good antag- 
onist for the 3.L2 TCR,  even at lower concentrations than 
Nva72 (Fig. 3). 
Peptides  That Induce  a Response through  the 3.L2  TCR  Can 
Be Ranked Based on Their Relative Activity.  From these stud- 
ies,  we  have  identified  11  peptides  that  differ  from  the 
wild-type Hb(64-76) peptide at position 72 but can still in- 
teract with  the  3.L2  TCR  in  some  manner.  We  next at- 12500 - 
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Figure 5.  Induction  of peptide-dependent  B cell 
apoptosis by the 3.L2 T cell clone. The agonist and 
antagonist peptides  that  were  identified  using the 
3.L2.12 hybridoma were tested for the ability to in- 
duce  apoptosis of  the  CH27  B  cell  lymphoma. 
Shown are the peptides that were positive in this as- 
say as well as the negative control peptide E72. Apop- 
tosis is measured by a reduction in counts due to flag- 
mentation of prelabeled CH27  DNA. The peptides 
$72, L72, and G72 did not induce any apoptosis even 
though these peptides were positive in the antagonist 
assay. The  values represent the  mean of triplicate 
wells, and the Sl)s were <15% of the mean. This ex- 
periment was performed four times. 
tempted to  use  a  single assay to  rank these  peptides based 
on their stimulatory capacity. The assay that we have used 
is the induction ofapoptosis in the B  cell lymphoma CH27 
by the 3.L2  clone.  This rapid and sensitive apoptosis assay 
has previously been used to identify APLs for other T  cell 
clones,  and  it  allows  agonists  and  partial  agonists  to  be 
compared on the same scale (26).  Apoptosis of CH27  can 
be  mediated  by  the  3.L2  clone  and  is  observed  over  a 
100,000-fold concentration range of peptides (Fig. 5).  The 
peptides that were identified as weak agonists require "-q0- 
100-fold  higher  concentrations  of peptide  than  wild-type 
Hb(64-76).  Peptides  that  were  antagonists  in  the  hybri- 
doma assay also induce apoptosis of CH27,  but at concen- 
trations that are 1,000-100,000-fold  higher than wild-type 
Hb(64-76).  However,  this  assay  appears  to  be  somewhat 
less sensitive  than  the  antagonist  assay, because  $72,  L72, 
and  G72  did not  induce  any  apoptosis of CH27.  Signifi- 
cantly, the order that the peptides fall into using the apop- 
tosis assay of the T  cell clone is the same  as that  obtained 
using the two separate lymphokine assays of the T  cell hy- 
bridoma. The advantage of using the apoptosis assay is that 
it allows us to quantitatively compare weak agonist and an- 
tagonist peptides in a single assay. 
Based on  the combination  of assays outlined above,  we 
could rank 12 peptides differing only in the structure of the 
side  chain  at  position 72  for  their  ability to  induce  a  re- 
sponse from the 3.L2 T  cell. A  schematic for the structure 
of each of these side chains and their relative activity in the 
3.L2  assays is  displayed in  Fig.  4.  The  Hb(64-76)  peptide 
was arbitrarily assigned an activity of 100,  and the relative 
activity for  the  peptides  Abu72  through  A72  was  deter- 
mined  by  the  relationship  between  the  concentration  of 
Hb(64-76) and the substituted peptide required for apopto- 
sis of 40% of the CH27 cells in the assay depicted in Fig. 5. 
Because $72,  L72, and G72 do not have any activity in the 
apoptosis assay,  a  relative activity was  estimated based  on 
the  antagonist  activity  of these  peptides  compared  with 
A72.  In antagonist assays, $72  and A72 acted at essentially 
the  same  concentration,  so  these  peptides  have  been  as- 
signed the same relative activity even though  $72 does not 
have any activity in the apoptosis assay. 
An  MHC  Contact  Residue  I,  fluences  TCR  Recognition. 
The substitution of the Glu at position 73  of the Hb pep- 
tide with Asp does not affect the affinity ofpeptide binding 
to  MHC  but  does  change  T  cell recognition  of the  pep- 
tide-MHC  complex (4,  24,  25).  Interestingly, this residue 
was  shown  to  be  an  MHC  binding residue  in  the  crystal 
structure  of  the  Hb(64-76)/I-E k  complex  (21).  For  the 
3.L2  TCR,  the  D73  peptide is a  weak  agonist,  requiring 
"-q0,000-fold higher concentration than Hb(64-76)  to in- 
duce IL-2 production from the 3.L2.12 hybridoma (Fig. 2). 
Because the position 73 residue does not contact the TCk 
directly, we wondered how a change at this position could 
affect TCR  recognition. One hypothesis is that a change at 
this  position  could  alter  the  conformation  of other  side 
chains either in the peptide or in the MHC  molecule. An- 
other possibility is that the TCP,. makes some contacts with 
atoms in the peptide backbone, and the accessibility of these 
atoms is changed by the D73 substitution. Of these sugges- 
tions,  one  of the  most  likely possibilities is  that  the  D73 
substitution causes the residue at position 72 to be in a dif- 
ferent conformation. We reasoned that if an Asp at position 
73  was  influencing the  side  chain  at  position  72,  then  it 
should  have  different  effects  depending  on  how  well  the 
position  72  side  chain  is  recognized.  We  tested  this  hy- 
pothesis by examining the influence of a D73 mutation on 
not only the peptide containing Asn at position 72, but also 
its effect on other position 72 amino acids. 
An analysis of the  effect of D73  on Ash,  Cys,  Thr,  and 
Val at position 72 is shown in Fig. 6. By analyzing the abil- 
ity of these doubly substituted peptides to induce IL-2 pro- 
duction from 3.L2.12, we have found that stronger agomsts 
at position 72 are more influenced by a change at position 
73. Hb(64-76)  is active at a concentration of 0.01  b~M, and 
the D73  mutation is active at a 3,000-fold higher concen- 
tration. The T72 and V72 peptides are not nearly as stimu- 
latory as the Hb(64-76)  peptide, and combining these mu- 
tations  with  the  D73  nmtation  only  shifts  the  response 
~10-fold.  These  results are consistent with the hypothesis 
that the amino acid at position 73 influences the confbrma- 
tion of the residue at position 72.  For a  residue at 72  that 
interacts very well with the 3.L2 TClq,, such as Asn, a slight 
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Figure 6.  A mutation in the MHC contact residue at 
position 73  of Hb(64-76) influences  recognition of the 
amino acid  at position 72.  Peptides  with single substi- 
tutions at position 72  or double substitutions at posi- 
tions 72 and 73 were tested  for the abili W to stimulate 
the  3.L2.12  hybridoma  to  produce  IL-2.  The  four 
graphs represent data obtained from a single agonist as- 
say that was performed in the same manner as the assay 
in Fig. 2. The data points represent the mean of tripli- 
cate  wells,  and  this  result  is  representative  of at  least 
three experiments. 
change  in  conformation  will  significantly  alter  the  effec- 
tiveness  of the  peptide.  However,  for residues  at  72  that 
have  a  less-than-optimal  interaction  with  the  3.L2  TCR, 
such as Thr, a slight change in conformation is not nearly as 
influential, because these residues already have a suboptimal 
fit with the TCR. We have tested other amino acids at po- 
sition  72  that  are  not  stimulatory  for  3.L2.12,  and  in  no 
case does addition of the D73 substitution cause conversion 
to a stimulatory peptide. 
Discussion 
In these studies we have identified some of the structural 
parameters  that  detemfine  how the  3.L2 TCR  recognizes 
its ligand.  By examination  of Hb(64-76)  peptides  that use 
all  20  naturally  occurring amino  acids  at  position  72,  we 
have determined that peptides using a side chain at position 
72  that  resembles  Asn are  the  peptides  that  induce  T  cell 
responses. Based on this knowledge, we rationally designed 
APLs that used nonnatural  amino  acid side  chains  at posi- 
tion 72.  In addition, we have found that even if the struc- 
ture of the position 72 side chain is unaltered,  an APL can 
be made by substitution  of the neighboring MHC  contact 
residue at position 73. These data suggest that a substitution 
at position 73 induces a conformational change in the posi- 
tion 72  side  chain,  thus  producing an  altered  ligand.  The 
data  show that a  single  TCIL can recognize a broad spec- 
trum of ligands that can stimulate  the T  cell over a  1 mil- 
lion-fold range of activity. 
Examination  of the structures of the side chains that in- 
duce a  response  through the  3.L2  TCB, reveals  a  correla- 
tion between structure and responsiveness. The response of 
the 3.L2 TCR  to the Abu-substituted peptide is ,'~1/20 of 
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the  response  to  the  peptide  with  an  Ash  side  chain.  The 
3.L2 T  cell also responds well to peptides with side chains 
that have a 13 and ",/carbon like Abu but have additions to 
the [3 carbon. T72 and V72 have only ~2.5-fold lower ac- 
tivity than Abu72, and these side  chains have an hydroxyl 
and a methyl group addition at the  [3 carbon, respectively. 
Larger additions at the [3 carbon are much more influential, 
as  I72  is  ~l,000-fold  lower  in  activity  than  AbuT2.  M- 
though this TCR  tolerates additions to the [3 carbon, addi- 
tions to the ~  carbon have greater consequences. Notably, 
the Nva side chain adds a methyl group to Abu and reduces 
the relative activity 2,500 times. This suggests that the 3.L2 
TCR  has  very strict  requirements  for recognition  of the 
amide structure  that is present  on the ~  carbon of the Ash 
side chain. Although the addition of one methyl group on 
the ~/carbon reduces activity 2,500-fold (Nva72) and addi- 
tion  of two  methyl  groups  reduces  activity  16,600-fold 
(L72),  not all  additions  to the y  carbon have  such  an ex- 
treme  effect; the  Pra72 peptide  has an activity that is only 
71-fold less than Abu72. Thus, among the amino acids that 
are larger than Abu, Pra has the side chain that most closely 
resembles  Asn structurally,  and  the  Pra72  peptide  has  the 
activity that most closely resembles Hb(64-76). 
The  data  suggest that  for the  type  of signaling  through 
the  3.L2  TCR  that leads  to antagonism,  the  side  chain at 
position  72  must  either  be  small  and  relatively  nonpolar 
(Ala,  Ser), or a little larger than Val and also nonpolar (Ile, 
Nva, Leu). Side chains that fall into an optimum size range 
and have limited polarity (Abu, Cys, Thr,  Val)  deliver the 
type of signal through the TCR  that makes a weak agonist. 
We would like to presume that the TCR  forms a binding 
surface that is able to accept a side chain with two carbons, 
and hydrophobic interactions between the TCR  and the [3 and 2~ carbons of the P5 side chain are very important, be- 
cause the wild-type Hb(64-76)  peptide only stimulates 20 
times better than the Abu72 peptide.  The contribution to 
binding  by TCR  residues  that  contact  the  amide  group 
may be responsible for the  increased  activity that  Hb(64- 
76)  has compared with Abu72. This part of the interaction 
would be highly specific because any addition made to the 
~/carbon of Abu reduced the activity of the peptide. 
The  clear correlation between  structure  and activity of 
these different ligands  allows us to conclude that the activity 
of the APLs depends on their ability to mimic the structure 
of the wild-type Asn residue. Similar structure/function re- 
lationships have been obtained in the study of interactions 
between  antigen  receptors  and  haptens.  For  B  cells,  the 
hapten TNP inhibited the effects of the hapten DNP on B 
cells  specific for DNP  (31).  The TNP ligand was thought 
to have a lower affinity for the DNP-specific B cell recep- 
tors  and  could  perhaps  interact  with  the  B  cell  receptor 
well enough  to block interaction with DNP but not well 
enough to induce a response on its own. T  cells specific for 
arsanylated ovalbumin have also been produced, and these 
can be thought of as a specialized case in which the TCR 
recognizes arsonate as if it were present at the P5 position 
of a peptide (32).  The response of T  cells specific for arson- 
ate can be inhibited by arsonate derivatives that have sub- 
stitutions on the aromatic ring (33). Again, it was suggested 
that the arsonate derivatives can interact well enough with 
the  TCR  to  compete with  arsonate  for binding  but  not 
well enough  to activate on their own,  although some de- 
rivatives were able to activate at high concentrations  (33). 
Therefore, we conclude that by making subtle changes in 
the  structure  of the P5 side  chain of Hb(64-76),  we have 
produced peptide-MHC complexes that interact well enough 
with the 3.L2 TCR  to induce some T  cell functions only 
at  high  concentrations  (B  cell  apoptosis)  and  inhibit  the 
ability of wild-type  Hb(64-76)  to  induce  other functions 
(antagonism). 
The wide range of activities seen in this study and data 
from numerous previous studies show that APLs can trigger 
T  cells in a fundamentally different way than the antigenic 
ligand (5). Although APLs need only be different from the 
antigenic ligand in a subtle manner,  how these subtle dif- 
ferences are translated into the observed differences in bio- 
logical response is  not  clear.  Current  theories  about how 
these  subtle  differences lead  to  different responses  can be 
grouped into the kinetic and conformational models (3). In 
a  kinetic  model,  the  TCR  has  a  reduced  affinity for the 
APL as compared to the wild-type ligand. This results in a 
reduction in the time that the TCR remains engaged with 
its ligand, that is, it has a faster off-rate. A short interaction 
with ligand then results in the transduction a different sig- 
nal through the TCR than that induced by the longer in- 
teraction with the wild-type ligand  (34,  35).  In a confor- 
mational  model,  the  transduction  of signals  through  the 
TCR involves some kind of conformational change in the 
TCR upon recognition ofligand. This change is not the same 
when a TCR recognizes an APL versus recognition of the 
wild-type ligand (36). 
Data acquired to  date  tend  to favor the  kinetic  model. 
Direct measurements of the affinity of a TCR  specific for 
I-E  k  presenting  an  MCC  peptide  and  its  analogs  have 
shown a correlation between the off-rate of the interaction 
and the  response of the  T  cell  (37,  38).  Peptides  that  are 
weak agonists or APLs have a faster off-rate for the mutant 
peptide-MHC  complex as compared to  the  wild-type li- 
gand (39). A study of the recognition of an ovalbumin pep- 
tide presented by K b has also shown a correlation between 
the  affinity  of the  TCR-MHC  interaction  and  the  re- 
sponse of the T  cell (28). 
Although  the  measurements  of these  off-rates certainly 
favors the kinetic model, it is still possible that a conforma- 
tional  change  is  also  occurring,  and  the  reduced  off-rates 
that are observed are only coincidental. The data presented 
in this study suggest that this is not the case,  and that it is 
the kinetic aspect of TCR-ligand interaction that is impor- 
tant  for APL function.  The important  observation is  that 
there is an optimum size for the side chain at position 72. If 
we consider the Abu side chain to be the closest mimetic of 
Asn  that  we  have,  then  it is  clear that both the  addition 
(Nva) and the subtraction (Ala) of a methyl group will have 
a similar effect. It easy to see how both of these changes can 
have  similar  effects  on  the  affinity  of the  TCR  for  its 
ligand. The extra methyl group would make the side chain 
too  bulky  and  not  allow  it  to  fit  as  well  into  a  binding 
pocket,  and  the  loss  of a  methyl  group  would  leave  not 
enough side chain to go into the binding pocket. It is diffi- 
cult,  however,  to  see  how  these  two  different  changes 
would lead to similar conformational changes in the TCR. 
Therefore,  these  data  are  consistent  with  a kinetic  model 
that  requires  the  affinity of the  TCR  for APLs  to be re- 
duced as compared to the cognate antigenic ligand. 
The high potential for the use of APLs in the treatment 
of disease  makes it desirable to be able to rationally design 
such  antigen  analogs once  the  antigenic  peptide  has been 
defined.  Previous  systematic studies  have  not  produced  a 
consistent  strategy  for  making  APLs  (13,  22,  23).  The 
strength of this study is that we have been able to find  12 
different side chains that interact with a single TCR from 
the same contact position. This is in part due to our ability 
to produce some altered peptides that use nonnatural amino 
acids at this critical position. Based on these data, we sug- 
gest that APLs can be produced by substituting  an amino 
acid  that  interacts  directly with  the  TCR  with  an  amino 
acid that structurally resembles that TCR  contact residue, 
Although many TCRs will be so highly dependent on the 
interaction provided by the primary TCR  contact residue 
that they will not tolerate any change at that position, evi- 
dence suggests that T  cells other than 3.L2 can be manipu- 
lated  at  the  primary TCR  contact.  For  example,  T  cells 
that  recognize  the  MCC  peptide  presented  by  I-E  k will 
recognize changes at the P5 position of the peptide as APLs 
(13),  and extensive analysis  of the hemagglutinin  307-319 
peptide  presented  by the  DR1  class  II molecule  showed 
that conservative substitutions at TCR contact residues were 
most likely to produce antagonist peptides (22).  Therefore, 
we conclude that APLs can be rationally designed by mak- 
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structures that resemble the structure of the antigenic ligand. 
By making such small changes in either size, hydropho- 
bicity, or conformation ofa TCR  contact residue, we have 
identified 16 different ligands for a single TCR  that have a 
1 million-fold range in activity. Such an extreme flexibility 
in TCP, recognition suggests that a large number of poten- 
tial ligands may exist for each individual TCtL. Conversely, 
for each peptide-MHC complex, a large number of TCRs 
may exist that will recognize that ligand well enough to in- 
duce a biological response. This study has also shown that 
there  is  a  strict  relationship  between  the  structure  of an 
amino acid side chain that interacts directly with the TCR 
and  how  that  T  cell will perceive that  ligand.  These  data 
are consistent with the idea that the affinity of the TCR- 
ligand interaction primarily determines the functional out- 
come  of that  interaction.  Ongoing  studies will determine 
the validity of this hypothesis. 
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